S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
NASDAQ:MOR

MorphoSys (MOR) Stock Price, News & Analysis

$18.06
+0.01 (+0.06%)
(As of 04/12/2024 08:52 PM ET)
Today's Range
$17.95
$18.06
50-Day Range
$16.27
$18.18
52-Week Range
$4.18
$18.31
Volume
568,400 shs
Average Volume
349,685 shs
Market Capitalization
$2.72 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.78

MorphoSys MarketRank™ Stock Analysis

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
34.8% Downside
$11.78 Price Target
Short Interest
Healthy
1.08% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.74mentions of MorphoSys in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.08) to ($0.89) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.67 out of 5 stars

Medical Sector

884th out of 928 stocks

Pharmaceutical Preparations Industry

399th out of 418 stocks

MOR stock logo

About MorphoSys Stock (NASDAQ:MOR)

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

MOR Stock Price History

MOR Stock News Headlines

Biden to Launch “FedNOW” [Move Your Money Now]
Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...
Novartis begins tender offer for MorphoSys
Novartis tender offer for MorphoSys AG commences
Biden to Launch “FedNOW” [Move Your Money Now]
Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...
MorphoSys AG ADR (MOR)
MorphoSys AG (MOR) Q4 2023 Earnings Call Transcript
NVS Apr 2024 80.000 call
Here's what Wall Street expects from Morphosys's earnings
Here's what Wall Street expects from MorphoSys's earnings report
See More Headlines
Receive MOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/13/2024
Today
4/14/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MOR
Employees
524
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.78
High Stock Price Target
$18.25
Low Stock Price Target
$4.75
Potential Upside/Downside
-34.8%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
8 Analysts

Profitability

Net Income
$-205,350,000.00
Pretax Margin
-80.13%

Debt

Sales & Book Value

Annual Sales
$257.89 million
Book Value
$0.35 per share

Miscellaneous

Free Float
150,546,000
Market Cap
$2.72 billion
Optionable
Not Optionable
Beta
1.17
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Jean-Paul Kress M.D.Dr. Jean-Paul Kress M.D. (Age 59)
    Chairman of Management Board, MD & CEO
    Comp: $1.91M
  • Dr. Lucinda Crabtree Ph.D. (Age 45)
    CFO & Member of Management Board
    Comp: $764.53k
  • Ms. Charlotte Lohmann (Age 54)
    Chief Legal and Human Resources Officer & Member of Management Board
    Comp: $513.54k
  • Mr. Klaus De Wall
    Head of Accounting & Tax
  • Dr. Margit Urban
    Head of Discovery Alliances & Technologies
  • Dr. Julia Neugebauer Ph.D.
    Head of Investor Relations
  • Dr. Barbara Krebs-Pohl Ph.D.
    Chief Business Officer
  • Dr. Günter Wellnhofer
    Head of Technical Operations
  • Dr. Harald Watzka
    Head of Alliance Management
  • Ms. Yen Ching Chua
    Head of Clinical Operations

MOR Stock Analysis - Frequently Asked Questions

Should I buy or sell MorphoSys stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MOR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOR, but not buy additional shares or sell existing shares.
View MOR analyst ratings
or view top-rated stocks.

What is MorphoSys' stock price target for 2024?

8 analysts have issued 1-year target prices for MorphoSys' stock. Their MOR share price targets range from $4.75 to $18.25. On average, they anticipate the company's share price to reach $11.78 in the next twelve months. This suggests that the stock has a possible downside of 34.8%.
View analysts price targets for MOR
or view top-rated stocks among Wall Street analysts.

How have MOR shares performed in 2024?

MorphoSys' stock was trading at $9.90 at the beginning of 2024. Since then, MOR stock has increased by 82.4% and is now trading at $18.06.
View the best growth stocks for 2024 here
.

Are investors shorting MorphoSys?

MorphoSys saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 1,630,000 shares, a decrease of 22.0% from the March 15th total of 2,090,000 shares. Based on an average trading volume of 2,010,000 shares, the short-interest ratio is presently 0.8 days.
View MorphoSys' Short Interest
.

When is MorphoSys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our MOR earnings forecast
.

How were MorphoSys' earnings last quarter?

MorphoSys AG (NASDAQ:MOR) posted its quarterly earnings results on Wednesday, March, 13th. The company reported $0.33 earnings per share for the quarter, beating the consensus estimate of ($0.92) by $1.25. The business had revenue of $63.53 million for the quarter, compared to the consensus estimate of $76.30 million. MorphoSys had a negative trailing twelve-month return on equity of 694.31% and a negative net margin of 80.07%.

What ETF holds MorphoSys' stock?

Range Cancer Therapeutics ETF holds 17,145 shares of MOR stock, representing 1.32% of its portfolio.

What is Simon E. Moroney's approval rating as MorphoSys' CEO?

5 employees have rated MorphoSys Chief Executive Officer Simon E. Moroney on Glassdoor.com. Simon E. Moroney has an approval rating of 100% among the company's employees. This puts Simon E. Moroney in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did MorphoSys IPO?

MorphoSys (MOR) raised $200 million in an IPO on Thursday, April 19th 2018. The company issued 8,300,000 shares at $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners served as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers.

How do I buy shares of MorphoSys?

Shares of MOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MOR) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners